What side effects are associated with this type of intervention?

Digital behavioral therapies, such as smartphone applications and text message-based programs, are increasingly used for nicotine addiction treatment. These methods generally have minimal physical side effects but may face challenges like low engagement and high dropout rates. Common side effects of pharmacotherapies, which are often used in conjunction with behavioral therapies, include nausea, insomnia, and vivid dreams (varenicline), dry mouth and insomnia (bupropion), and skin irritation (nicotine patches). Behavioral interventions like counseling and mindfulness practices typically have no significant physical side effects but require consistent participation and motivation.

What prior FDA approvals exist?

The FDA has approved several pharmacological treatments for nicotine addiction, including nicotine replacement therapies (NRTs) such as patches, gums, and lozenges, as well as prescription medications like bupropion (Zyban) and varenicline (Chantix). These treatments are often used in combination with behavioral therapies to increase their effectiveness. While digital behavioral therapies are emerging as a promising approach, specific FDA approvals for digital interventions targeting nicotine addiction are still limited. However, digital platforms and smartphone applications, like the one being studied in the ACT on Vaping trial, are gaining traction as supportive tools in smoking cessation programs.

What other types of research exist?

Promising alternatives to ACT on Vaping for nicotine addiction treatment in 2024 include: 1) Mobile phone text messaging programs, which have shown effectiveness in smoking cessation. 2) Internet-based interventions, which provide accessible and scalable support. 3) Smartphone applications specifically designed for smoking cessation, such as those reviewed in various studies. 4) Social network-based interventions like Tweet2Quit, which leverage social support for quitting smoking. 5) Comprehensive digital platforms like the National Cancer Institute's Smokefree.gov Initiative, offering multimodal digital support.

← Back to Search

Smartphone App for Vaping Cessation

N/A

Waitlist Available

Led By Jaimee Heffner

Research Sponsored by Fred Hutchinson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 3 months post-randomization

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a digital program called 'ACT on Vaping' that uses a smartphone app and text messages to help young adults quit vaping. The program targets young adults who use e-cigarettes and are at risk of nicotine addiction. The app and texts remind users to check their vaping habits and offer support to quit.

Who is the study for?

This trial is for young adults aged 18-30 in the US who use e-cigarettes at least weekly, own a smartphone (Android or iPhone), and have an email address. They must be willing to complete all study procedures and have a US mailing address.

What is being tested?

The trial is testing 'ACT on Vaping,' a digital program designed to help young adult e-cigarette users quit vaping. It involves using a smartphone app, receiving text messages, and completing surveys.

What are the potential side effects?

Since this intervention involves using a smartphone application and communication via text message rather than medication, traditional side effects are not expected. However, participants may experience stress or frustration related to quitting vaping.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in readiness to quit

Cotinine-confirmed 30-day point prevalence abstinence from all nicotine and tobacco

Overall treatment satisfaction rating

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (Act on Vaping app)Experimental Treatment3 Interventions

Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.

Group II: Arm II (Incentivized text message check-ins)Active Control2 Interventions

Participants receive incentivized text messages check-ins assessing their vaping status.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Smartphone app

2019

N/A

~190

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for nicotine addiction include pharmacologic therapies like nicotine replacement therapy (NRT), varenicline, and bupropion, which work by reducing withdrawal symptoms and cravings. NRT provides a controlled dose of nicotine, varenicline partially stimulates nicotine receptors, and bupropion affects neurotransmitters to reduce the urge to smoke. Behavioral therapies, such as digital behavioral therapy programs like ACT on Vaping, focus on changing habits and thought patterns associated with nicotine use through techniques like motivational interviewing and cognitive-behavioral strategies. These combined approaches are more effective as they address both the physical and psychological aspects of addiction, providing a comprehensive treatment plan for patients.

Electronic Cigarette Cessation in Youth and Young Adults: A Case Series.